Prelude Capital Management’s Tectonic Therapeutic TECX Stock Holding History

Prelude Capital Management’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,841	Closed	-$362K	–	1583
2024 Q4	$362K	Hold	7,841	–	–	0.02%	722
2024 Q3	$238K	Buy	+7,841	New	+$143K	0.01%	982
2022 Q2	–	Sell	-1,400	Closed	-$22K	–	2110
2022 Q1	$22K	Sell	1,400 -292	-17%	-$6.03K	﹤0.01%	1535
2021 Q4	$78K	Buy	+1,692	New	+$97.2K	﹤0.01%	1753
2020 Q4	–	Sell	-8	Closed	-$1K	–	2095
2020 Q3	$1K	Buy	+8	New	+$1.61K	﹤0.01%	1745
2019 Q3	–	Sell	-36	Closed	-$7K	–	2124
2019 Q2	$7K	Buy	+36	New	+$7.76K	﹤0.01%	1472
2018 Q4	–	Sell	-1,083	Closed	-$674K	–	2222
2018 Q3	$674K	Buy	+1,083	New	+$480K	0.04%	451

Other funds holding TECX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Prelude Capital Management's TECX Position: Q1 2025 in Review

Prelude Capital Management sold out of Tectonic Therapeutic (TECX) in Q1 2025, closing a stake of 7,841 shares — an estimated $362K sold.

Prelude Capital Management first reported a position in TECX in Q3 2018 and held it in 7 quarters. The position peaked at $674K in Q3 2018. 78 funds tracked by Wall St. Rank hold TECX as of Q1 2025.

Prelude Capital Management reported no remaining Tectonic Therapeutic position as of Q1 2025 after selling out during the quarter.
Prelude Capital Management sold 7,841 Tectonic Therapeutic shares in Q1 2025, an estimated $362K.
Prelude Capital Management first reported a position in Tectonic Therapeutic in Q3 2018 and held it in 7 quarters.
Prelude Capital Management's Tectonic Therapeutic position peaked at $674K in Q3 2018.
78 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.